Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL717526 | 1.00 | TSHR (0.48) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11795376 | 0.83 | KMT2A (0.47) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10877958 | 0.83 | MAPT (0.50) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4398048 | 0.83 | ALDH1A1 (0.47) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| Toluene SCHEMBL26121009 | 0.83 | TSHR (0.44) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11795381 | 0.83 | KMT2A (0.47) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10877963 | 0.83 | MAPT (0.50) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15843753 | 0.83 | ALDH1A1 (0.56) | TSHRALDH1A1KMT2AGAAPOLB | |
| SCHEMBL15843754 | 0.83 | ALDH1A1 (0.56) | TSHRALDH1A1KMT2AGAAPOLB | |
| SCHEMBL263877 | 0.83 | ALDH1A1 (0.47) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| CN-113365632-A | Aminopyrimidine compounds | 卡都瑞恩医药有限责任公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20050148624-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885SMN1; SMN2 702/4885 |
| US-20050148624-A1 | Jnk inhibitor | MAPK3, MAPKAPK3, MAPK1 | TSHR 2858/4885ALDH1A1 4549/4885SMN1; SMN2 4193/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885SMN1; SMN2 702/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885SMN1; SMN2 702/4885 |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | TSHR 1907/4885ALDH1A1 743/4885SMN1; SMN2 4203/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | TSHR 808/4885ALDH1A1 118/4885SMN1; SMN2 4093/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885SMN1; SMN2 702/4885 |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | IRAK1, IRAK2, IRAK4 | TSHR 2793/4885ALDH1A1 927/4885SMN1; SMN2 3105/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885SMN1; SMN2 702/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | TSHR 1888/4885ALDH1A1 1362/4885SMN1; SMN2 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.